Position in ABBV
as of Jun 30, 2026
· filed Jul 21, 2026
Position Value
$282,088
+$21,535 QoQ
Shares Held
1,121
-6.4% QoQ
Ownership
0.000%
of shares outstanding
% of Portfolio
0.13%
of 13F equity value
Holder Rank
#3,675
of 4,150 holders
Holding Since
Mar 2025
4 quarters on record
Voting authority
Sole 0%
Shared 0%
None 100%
Common Shares in ABBV Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - General
Healthcare · as of Jun 30, 2026Triumph Capital Management holds $8,936,522 across 15 Drug Manufacturers - General names. ABBV ranks #8 (3.2% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | LLY |
ELI LILLY & Co
|
3,038 | $3,643,868 | |
| 2 | PFE |
Pfizer Inc
|
60,207 | $1,449,784 | |
| 3 | BMY |
Bristol Myers Squibb Co
|
20,678 | $1,191,466 | |
| 4 | JNJ |
Johnson & Johnson
|
2,531 | $642,798 | |
| 5 | AMGN |
Amgen Inc
|
1,644 | $595,325 | |
| 6 | GILD |
Gilead Sciences, Inc.
|
3,687 | $465,815 | |
| 7 | MRK |
Merck & Co., Inc.
|
2,699 | $346,821 | |
| 8 | ABBV |
AbbVie Inc.
This page
|
1,121 | $282,088 |
All Filings in ABBV
Export CSV
4 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $282,088 | 1,121 | Shares | Sole | 2026-07-21 | |
| 2026-03-31 | $260,553 | 1,198 | Shares | Sole | 2026-05-13 | |
| 2025-12-31 | $271,903 | 1,190 | Shares | Sole | 2026-02-12 | |
| 2025-03-31 | $213,500 | 1,019 | Shares | Sole | 2025-05-06 | |
| No filing history on record for this holder in this stock. | ||||||